Vanberra Signal
Free trial

Daytrana

Curated by Signal

Methylphenidate transdermal system for the management of ADHD

Life Sciences Technologydaytrana.com

Overview

Daytrana is a developer of methylphenidate transdermal system for the management of ADHD. The device is a patch is used once-a-day and it is available in four sizes. Each size delivers a different dosage strength designed to help manage the symptoms of ADHD in children ages 6-17. The suggested starting dose is 10 mg both for patients new to methylphenidate and for patients switching from another ADHD medication. The patch is prescription based and it is claimed to provide up to 10 hours of efficacy.

Key facts

Founded
2005
Headquarters
Miami, United States
Stage
Sign up to view
Industry
Life Sciences Technology

Contact

Primary office
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

  • Nanocrine

    Provider of a cell analysis and drug design tool for researchers

    Life Sciences TechnologyFrederick, United States

  • 1Balance

    Manufacturer of herbal supplements for menopause support

    Life Sciences TechnologySan Francisco, United States

  • HALE life

    Information engine for clinical decision support and personalized care plans

    Life Sciences TechnologyHoboken, United States

About Daytrana

What does Daytrana do?

Daytrana is a developer of methylphenidate transdermal system for the management of ADHD.

Where is Daytrana headquartered?

Daytrana is headquartered in Miami, United States.

When was Daytrana founded?

Daytrana was founded in 2005.

Which sector is Daytrana in?

Daytrana operates in Life Sciences Technology.

Who are Daytrana's competitors?

Companies similar to Daytrana include Nanocrine, 1Balance, and HALE life.